Reflections on Charlie Gard and the Best Interests Standard From Both Sides of the Atlantic Ocean

Author:

Ross Lainie Friedman1

Affiliation:

1. The College and Departments of Pediatrics, Medicine, and Surgery, University of Chicago, Chicago, Illinois

Abstract

Charlie Gard (August 4, 2016, to July 28, 2017) was an infant in the United Kingdom who was diagnosed with an encephalopathic form of mitochondrial DNA depletion syndrome caused by a mutation in the RRM2B gene. Charlie’s parents raised £1.3 million (∼$1.6 million US) on a crowdfunding platform to travel to New York to pursue experimental nucleoside bypass treatment, which was being used to treat a myopathic form of mitochondrial DNA depletion syndrome caused by mutations in a different gene (TK2). The case made international headlines about what was in Charlie’s best interest. In the medical ethics community, it raised the question of whether best interest serves as a guidance principle (a principle that provides substantive directions as to how decisions are to be made), an intervention principle (a principle specifying the conditions under which third parties are to intervene), both guidance and intervention, or neither. I show that the United Kingdom uses best interest as both guidance and intervention, and the United States uses best interest for neither. This explains why the decision to withdraw the ventilator without attempting nucleoside bypass treatment was the correct decision in the United Kingdom and why the opposite conclusion would have been reached in the United States.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology, and Child Health

Reference47 articles.

1. Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency;Garone;EMBO Mol Med,2014

2. Begley S. 5 things to know about the experimental therapy for Charlie Gard. STAT. July 17, 2017. Available at: https://www.scientificamerican.com/article/5-things-to-know-about-the-experimental-therapy-for-charlie-gard/. Accessed July 7, 2020

3. Deoxynucleoside therapy for thymidine kinase 2-deficient myopathy;Domínguez-González;Ann Neurol,2019

4. Charles GARD and Others Against the United Kingdom;European Court of Human Rights,2017

5. Burton TI. Why terminally ill infant Charlie Gard’s case has created a global controversy. Vox. 2017. Available at: https://www.vox.com/identities/2017/7/6/15923758/charlie-gard-global-controversy-trump-francis. Accessed July 1, 2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3